About Prostate cancer

• Prostate cancer (PCa) is the second most frequent malignancy (after lung cancer) in men worldwide​.
• PCa causes more than 400,000 deaths annually worldwide, and by 2040, the mortality rate is expected to reach more than 800,000 deaths annually.
• 1 in 8 men will be diagnosed with prostate cancer in their lifetime.
• Men from African descent have the highest incidence rates and more aggressive type of prostate cancer compared to  other ethnicities.

Our Mission

• Through research and development, Pi-SMA Therapeutics is aiming to bring to the clinic new therapies to treat prostate cancer and metastatic castration-resistant prostate cancer
• Our goal is to deliver first-in class, safe and efficacious therapies to dramatically reduce mortality and improve quality of life for men living with prostate cancer.